Materiały źródłowe

• #1

  https://www.nhs.uk/conditions/alcohol-related-liver-disease-arld/treatment/

  Successful treatment for alcohol-related liver disease (ARLD) often depends on whether someone is willing to stop drinking alcohol and make changes to their lifestyle. […] Treatment for ARLD involves stopping drinking alcohol. This is known as abstinence, which can be vital depending on what stage the condition is at. […] If you have a more serious form of ARLD (alcoholic hepatitis or cirrhosis) lifelong abstinence is recommended. […] This is because stopping drinking is the only way to prevent your liver damage getting worse and potentially stop you dying of liver disease. […] Nevertheless, if you have alcohol-related cirrhosis or alcoholic hepatitis and do not stop drinking, no medical or surgical treatment can prevent liver failure. […] Once you have stopped drinking, you may need further treatment to help ensure you do not start drinking again.

• #2 Alcoholic Liver Disease Treatment | Hepatitis, Cirrhosis – UChicago Medicine

  https://www.uchicagomedicine.org/conditions-services/liver-diseases-hepatology/alcoholic-liver-disease

  Physicians at the University of Chicago Medicine Center for Liver Diseases offer the latest innovative treatments for alcoholic liver disease, including liver transplantation for patients who may not have had this option in the past. Our liver transplant experts understand the complex medical and psychological needs of patients with alcoholic liver disease and work together with social workers, psychologists and psychiatrists to ensure you receive the highest level of personalized care and support. […] The most important part of treating alcoholic liver disease is to permanently stop all alcohol consumption. Your health care team can help you find programs to support you on this critical undertaking, including both inpatient and outpatient treatment programs at UChicago Medicine. Additionally, treatment for alcoholic liver disease may involve: […] The most important treatment you can undertake is to permanently stop drinking alcohol to give your liver the chance to rest and heal as much as possible. Depending on the severity of damage to your liver and your specific illness, your treatment may involve:

• #3 Alcohol-related Liver Disease > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/alcohol-related-liver-disease

  Treatments include abstinence from alcohol, dietary changes, medications, and liver transplantation. […] The single best treatment for alcohol-related liver disease is abstinence from alcohol. When indicated, specific treatments are available that can help people remain abstinent, reduce liver inflammation, and, in the case of liver transplantation, replace the damaged liver. […] Abstinence from alcohol is the recommended in all cases to prevent further injury and complications, says Lamia Haque, MD, MPH, Director of the Yale Clinic for Alcohol and Addiction Treatment in Hepatology and Digestive Diseases. Treatment for alcohol-related liver disease requires a multifaceted and individualized approach including nutritional support, treatment of coexisting alcohol use disorder, and in severe cases, medications to treat inflammation and complications of advanced liver disease as well as liver transplantation.

• #3 Alcohol-related Liver Disease > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/alcohol-related-liver-disease

  To be considered for a liver transplant, patients must remain abstinent from alcohol prior to transplantation surgery. The purpose of this is to ensure that patients are able to maintain abstinence and are likely to remain abstinent after the transplant surgery. […] The treatment of alcohol-related liver disease requires a multidisciplinary approach, says Dr. Haque. Our team at Yale Medicine includes experts in liver diseases, addiction medicine/psychiatry, nutrition, and liver transplantation to provide a comprehensive, individualized, and evidence-based treatment plan for each patient at any stage of alcohol-related liver disease.

• #4 Treatment of Alcoholic Liver Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5572973/

  Cessation of alcohol is necessary to treat alcoholic liver disease. If the patient has simple fatty liver, then cessation will allow the liver to heal and return to normal. If a patient has alcohol-induced fibrosis or cirrhosis and abstains from alcohol, damage to the liver will stop and the liver will get better, although liver scar tissue will remain. In some patients, the fibrosis seems to regress. Fibrosis regression is difficult to document and cannot be predicted in an individual patient who stops drinking. In most patients, the fibrosis remains to some degree, potentially as much as when the patient stopped drinking. For alcoholic hepatitis or foamy fatty change, stopping alcohol is necessary and will lead to improvements in most patients but may not be sufficient to stop the disease.

• #5 Alcohol-related liver disease | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/alcohol-related-liver-disease/

  Theres currently no specific medical treatment for ARLD. The main treatment is to stop drinking, preferably for the rest of your life. This reduces the risk of further damage to your liver and gives it the best chance of recovering. […] A liver transplant may be required in severe cases where the liver has stopped functioning and doesnt improve when you stop drinking alcohol. […] Successful treatment for alcohol-related liver disease (ARLD) often depends on whether someone is willing to stop drinking alcohol and make changes to their lifestyle. […] Treatment for ARLD involves stopping drinking alcohol. This is known as abstinence, which can be vital, depending on what stage the condition is at. […] If you have a more serious form of ARLD alcoholic hepatitis or cirrhosis life-long abstinence is recommended. This is because stopping drinking is the only way to prevent your liver damage getting worse and potentially stop you dying of liver disease.

• #5 Alcohol-related liver disease | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/alcohol-related-liver-disease/

  Nevertheless, if you have alcohol-related cirrhosis or alcoholic hepatitis and dont stop drinking, no medical or surgical treatment can prevent liver failure. […] In the most serious cases of ARLD, the liver loses its ability to function, leading to liver failure. A liver transplant is currently the only way to cure irreversible liver failure.

• #6 Alcoholic liver disease: Symptoms, treatment, and causes

  https://www.medicalnewstoday.com/articles/215638

  The first step in treating any level of alcoholic liver disease focuses on removing alcohol from the diet. […] This can help to reverse some early stages of liver disease. For example, stopping drinking once diagnosed with fatty liver disease may be able to reverse the condition within 26 weeks. […] Once a doctor diagnoses a person with alcoholic liver disease at any stage, they will recommend them to never resume drinking. Any conditions that have reversed will typically return once drinking restarts. […] Those who regularly drink more than the recommended daily limits of alcohol should not stop drinking without medical support. Withdrawal from alcohol can be life threatening. Individuals should seek help from a medical professional to safely manage alcohol withdrawal. […] Cognitive behavioral therapy (CBT) and medications called benzodiazepines can ease withdrawal symptoms in a person with alcohol dependency. People with severe alcohol dependency may stay at an inpatient rehabilitation facility for closer monitoring.

• #7 Alcohol-related liver disease (ARLD) – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/alcohol-related-liver-disease/

  Your liver is the only internal organ that can repair itself. If you can stop drinking alcohol and eat healthily, you’ll reduce the risk of further damaging your liver and give it the best chance of recovering. […] If your liver disease is at an early to moderate stage the aim will be to cure your condition, by: giving your liver a chance to repair itself, preventing further damage. […] If it’s more advanced, your treatment will aim to stabilise your liver disease and stop it from getting worse. You will be treated for any complications, such as bloating (ascites) or bleeding (varices). […] If you have alcohol-related fatty liver, the damage may be reversed if you stop for a period of time (months or years). After this, it’s usually safe to start drinking again if you stick to the recommended government guidelines.

• #8

  https://www.nhs.uk/conditions/alcohol-related-liver-disease-arld/

  There’s currently no specific medical treatment for ARLD. The main treatment is to stop drinking, preferably for the rest of your life. […] This reduces the risk of further damage to your liver and gives it the best chance of recovering. […] If a person is dependent on alcohol, stopping drinking can be very difficult. […] But support, advice and medical treatment may be available through local alcohol addiction support services. […] A liver transplant may be required in severe cases where the liver has stopped functioning and does not improve when you stop drinking alcohol. […] You’ll only be considered for a liver transplant if you have developed complications of cirrhosis despite having stopped drinking. […] All liver transplant units require people with ARLD to not drink alcohol while awaiting the transplant, and for the rest of their life.

• #9 Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action | Addiction Science & Clinical Practice | Full Text

  https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-024-00448-8

  Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. […] Therefore, there is an urgent need for innovative treatment strategies to improve care for this often marginalized subset of patients. […] The cornerstone of treatment for ALD at any stage is cessation of alcohol intake. Abstinence from alcohol is the most significant predictor of survival among patients ALD. […] Treatment of AUD can have significant implications for liver-related health in patients with ALD. […] These findings highlight the importance of linking patients with ALD to AUD treatment and, indeed, society guidelines and consensus statements on the management of ALD recommend that clinicians caring for patients with ALD provide or facilitate AUD treatment.

• #9 Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action | Addiction Science & Clinical Practice | Full Text

  https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-024-00448-8

  Despite the strong association between alcohol intake and mortality in ALD as well as emerging evidence demonstrating the beneficial impact of AUD treatment on clinical outcomes in those with ALD, few individuals with ALD receive AUD care. […] The low levels of AUD treatment receipt among patients with ALD highlight the pressing need for new approaches to transcend these barriers and underscore the importance of emerging integrated care models for ALD and AUD. […] Integrated care models for ALD and AUD aim to facilitate or directly provide treatment for both ALD and AUD simultaneously.

• #10 Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action | Addiction Science & Clinical Practice | Full Text

  https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-024-00448-8

  Treatment options for unhealthy alcohol use and AUD in ALD have been discussed extensively in several review articles in recent years. […] Among non-pharmacologic treatments, cognitive behavioral therapy and motivational enhancement therapy have the most robust evidence. […] Furthermore, providing behavioral treatment integrated with liver disease management have been shown to improve rates of abstinence. […] Treating AUD involves the use of medications to treat alcohol withdrawal as well as medications that promote abstinence primarily by reducing alcohol cravings. […] Disulfiram, naltrexone, and acamprosate are approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency to treat AUD. […] Overall, despite their efficacy, only 10% of those with AUD receive any form of treatment, and less than 1% of those with AUD receive any FDA-approved medications.

• #11 How Do I Manage Alcohol Use Disorder in Hepatology Clinic? | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/how-do-i-manage-alcohol-use-disorder-hepatology

  E. This patient has evidence of decompensated cirrhosis and impaired synthetic function. Although not FDA-approved for the treatment of alcohol use disorder, baclofen can be used off-label for treatment of alcohol use disorder and has been safe and effective for treating alcohol use disorder in patients with cirrhosis. Acamprosate is an FDA-approved medication for the treatment of alcohol use disorder and is primarily renally metabolized. A recent retrospective study demonstrated similar outcomes to baclofen in patients with liver dysfunction and decreased hospitalizations. Disulfiram and naltrexone have not been well-studied in patients with decompensated cirrhosis. Disulfiram has been associated with drug-induced liver injury, and naltrexone is hepatically metabolized. These medications should be avoided if better-studied alternatives are available.

• #12 How Do I Manage Alcohol Use Disorder in Hepatology Clinic? | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/how-do-i-manage-alcohol-use-disorder-hepatology

  Baclofen is a GABAB agonist and although not FDA-approved for the treatment of AUD, is the most well-studied medication for treating AUD in patients with ALD. Since the first randomized trial was published in 2007, which demonstrated significant improvement in alcohol abstinence in patients with cirrhosis, other studies have supported its use. […] Acamprosate is an FDA-approved medication for treatment of AUD. Although renally metabolized with no known hepatoxicity, this medication had not been formally studied in patients with ALD or cirrhosis until 2021, when Tyson et al performed a retrospective cohort study of patients with cirrhosis who were prescribed baclofen or acamprosate for AUD. No significant differences in side effects or abstinence were observed, although patients with acamprosate had fewer hospitalizations.

• #13

  https://link.springer.com/article/10.1007/s40265-023-01939-9

  Provision of behavioural treatment can be through brief interventions, motivational interviewing, cognitive behavioural therapy (CBT) or motivational enhancement therapy. CBT has the most consistent evidence for increasing abstinence in ALD, although data are limited. In ALD, where behavioural treatment is provided as part of an integrated hepatology clinic, rather than by external providers, there is evidence of improved abstinence and less severe relapse. Peer-led support programmes are widely available and at no financial expense to participants, including alcoholics anonymous (AA), an abstinence-only model based on 12-step principles that has Cochrane review evidence for increased abstinence. Self-Management and Recovery Training (SMART Recovery) is another model, based on self-empowerment and self-efficacy. Neither have evidence in a population with ALD specifically.

• #13

  https://link.springer.com/article/10.1007/s40265-023-01939-9

  Abstinence from alcohol is the cornerstone of treatment and should be recommended to all patients with ALD. Abstinence reduces the risk of hepatic decompensation and death in both compensated and decompensated cirrhosis patients. Multiple treatment modalities are available, including behavioural therapy, peer-led support programmes, and pharmacotherapy. Treatment recommendations and goals of care should be individually tailored based on the patient preferences, and underpinned by patient-centred care and shared decision making. In patients with ALD, the combination of comprehensive medical care and psychosocial interventions are more likely to result in abstinence, and integrated care approaches are associated with better outcomes. […] Single specialties are ill-equipped to manage the complexities of ALD alone, as holistic treatment requires simultaneous consideration of comorbid liver disease, alcohol use disorder (AUD), mental illness, and other psychosocial issues. Integrated models of care delivery exist as standard of care for the management of other comorbid physical and mental health conditions. However, integrated multidisciplinary models of care delivery in ALD are rare outside LT centres, and have been identified as an area of need to reduce the burden of ALD. Team members may include a hepatologist, addiction specialist, psychiatrist, counsellor, social worker, liver nurse and dietitian. Small studies have shown encouraging results, including a reduction in emergency department visits and inpatient admissions.

• #14

  https://link.springer.com/article/10.1007/s40265-023-01939-9

  There is evidence that alcohol pharmacotherapy is well tolerated and effective in patients with AUD, however caution is needed in patients with advanced liver disease due to the lack of safety data and the potential for hepatotoxicity. Alcohol pharmacotherapy is underprescribed in ALD and there is also evidence that gastroenterologists and hepatologists lack confidence and experience in prescribing it. Furthermore, safety data in ALD are limited given many trials excluded these patients. Baclofen has evidence of safety and efficacy in AUD and is the only pharmacotherapy with randomised controlled trial evidence in ALD, including in patients with cirrhosis. Acamprosate has evidence of efficacy in AUD, from a meta-analysis of 22 placebo-controlled trials, and is not recommended in Child-Pugh C cirrhosis, although this is based on tolerability of the drug after only a 1-day trial in Child-Pugh A and B cirrhosis. Naltrexone is well tolerated in compensated cirrhosis, but dose-dependent hepatotoxicity has been demonstrated in obesity trials and monitoring of liver function tests is recommended. Disulfiram can also lead to hepatotoxicity and is not recommended in advanced liver disease. Acamprosate, disulfiram and naltrexone (oral tablet and extended-release intramuscular injection) are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in AUD. Additionally, nalmefene is approved by the EMA, baclofen is approved in France, and sodium oxybate is approved in Italy and Austria. Gabapentin and topiramate are used off-label in AUD. Topiramate is recommended for AUD treatment by the US Department of Veterans Affairs and the American Psychiatric Association (APA) and gabapentin is recommended by the APA.

• #15 Alcohol-related liver disease: A global perspective | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-alcohol-related-liver-disease-a-global-S166526812400293X

  Alcohol-associated liver disease (ALD) represents one of the deadliest yet preventable consequences of excessive alcohol use. […] Early diagnosis, referral, and treatment are pivotal to achieving the therapeutic goal in patients with alcohol use disorder (AUD) and ALD, where complete alcohol abstinence and prevention of alcohol relapse are expected to enhance overall survival. This can be achieved through a combination of cognitive behavioral, motivational enhancement and pharmacological therapy. Furthermore, the appropriate use of available pharmacological therapy and implementation of public policies that comprehensively address this disease will make a real difference. […] Total alcohol abstinence and alcohol relapse prevention are the goals of therapy in patients with AUD and ALD, with the combination of cognitive-behavioral therapy, motivational enhancement therapy, 12-step programs (e.g., Alcoholics Anonymous), and pharmacotherapy.

• #16 Alcohol-related liver disease: A global perspective | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-alcohol-related-liver-disease-a-global-S166526812400293X

  Currently, there are only three Food and Drug Administration (FDA) – approved medications for alcohol use disorder (MAUD), disulfiram, acamprosate, and naltrexone, which have been associated with improved rates of abstinence, reduced binge drinking, and decreased rate of AUD-related hospitalizations. […] In a recent retrospective cohort study, pharmacotherapy for AUD improved survival in patients with alcohol-associated cirrhosis and AUD with a 20 % reduced hazard ratio of all-cause mortality (HR 0.80, 95 % CI 0.67-0.97). […] Naltrexone, acamprosate, gabapentin, topiramate, and baclofen are considered safe in patients with cirrhosis, although evidence is mostly derived from retrospective data. […] One of the most important challenges we face nowadays is that these medications are being underutilized by physicians, with multiple reasons being involved, such as lack of access, cost, discomfort when prescribing them, and concerns about safety and efficacy, reflecting a lack of exposure to AUD pharmacotherapy and participation in addiction clinics during training.

• #17 Treatment of Alcoholic Liver Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5572973/

  Currently, there are no treatments for fatty liver, alcoholic fibrosis, or alcoholic cirrhosis other than abstinence from alcohol. The only disease for which there is specific treatment is alcoholic hepatitis. Researchers have studied corticosteroids and pentoxifylline for many years in patients with alcoholic hepatitis. Most experts recommend prednisolone at a dose of 40 mg a day for 28 or 30 days as the preferred treatment for severe alcoholic hepatitis. Some experts prefer pentoxifylline instead. The most recent data suggest that prednisolone improves survival at 1 month. However, the beneficial effects disappear by 3 to 6 months. This was especially true in the STOPAH (Steroids or Pentoxifylline for Alcoholic Hepatitis) trial. […] Generally speaking, hepatologists recommend prednisolone or pentoxifylline when the Maddrey discriminant function score is greater than or equal to 32. Some doctors use the Model for End-Stage Liver Disease (MELD) score instead and start treatment if the patients MELD score is greater than or equal to 20. As mentioned above, the usual treatment duration is 28 or 30 days. I recommend adding magnesium, 1 pill a day, for many months. Magnesium may decrease intestinal permeability, an important component of reducing endotoxin absorption and exposure to the liver.

• #18 Alcoholic liver disease: Treatment

  https://www.wjgnet.com/1007-9327/full/v20/i36/12934.htm

  Alcoholic steatosis can be reversed after abstinence for several weeks. […] In particular, in patients with severe alcoholic hepatitis, steroid or pentoxifylline can be used according to recommendations of the guidelines. […] Corticosteroids (prednisolone 40 mg/d for 28 d followed by tapering over 2-4 wk) are the mainstay of treatment for severe alcoholic hepatitis. […] Pentoxifylline (400 mg 3 times/d for 28 d) is considered as an alternative to corticosteroid treatment in patients with severe alcoholic hepatitis. […] Anti-TNF- agents have been developed to block TNF-, a major cytokine involved in alcoholic hepatitis. […] Silymarin, a milk thistle extract with anti-oxidative and anti-fibrotic properties, has been evaluated in many studies as a potential treatment agent for ALD. […] Liver transplantation may be considered in the specific group of patients whose severe alcoholic hepatitis has failed medical treatment. […] New treatments or strategies are required to improve the survival of patients with ALD.

• #19 Treatment of alcoholic liver disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3036962/

  Glucocorticoids have been found to be beneficial in patients with hepatic encephalopathy and/or in patients with a Maddreys DF score 32 or MELD score 21. […] Pentoxifylline is thought to improve outcomes in alcoholic hepatitis via downregulation of pro-inflammatory cytokines. […] Orthotopic liver transplant (OLT) remains the only definitive treatment for hepatic failure associated with ALD.

• #19 Treatment of alcoholic liver disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3036962/

  Abstinence is the hallmark of therapy for ALD, and nutritional therapy is the first line of therapeutic intervention. […] The role of steroids in patients with moderate to severe alcoholic hepatitis is gaining increasing acceptance, with the caveat that patients be evaluated for the effectiveness of therapy at 1 week. Pentoxifylline appears to be especially effective in ALD patients with renal dysfunction/hepatorenal syndrome. […] Transplantation is effective in patients with end-stage ALD who have stopped drinking (usually for 6 months), and both long-term graft and patient survival are excellent. […] At present, abstinence remains the cornerstone for successful treatment of ALD. […] Pharmacotherapy in combination with psychosocial interventions can aid patients in maintaining abstinence from alcohol. Naltrexone and acamprosate have been shown to assist in reducing or eliminating alcohol intake in chronic heavy drinkers.

• #20 Alcoholic Hepatitis (Alcohol-Associated Hepatitis) Treatment & Management: Approach Considerations, Cessation of Alcohol Intake, Diet and Nutritional Support

  https://emedicine.medscape.com/article/170539-treatment

  For patients with milder alcoholic hepatitis, a general diet containing 100 g/d of protein is appropriate. Provide supplemental multivitamins and minerals, including folate and thiamine. Salt restriction may be required in patients with ascites. […] Additional treatment includes nutritional support. […] Use of medications in alcoholic hepatitis has been considered controversial. Many treatments discussed in the Medication section are still investigational. […] However, according to the 2019 American Association for the Study of Liver Diseases (AASLD) alcohol-associated liver disease guidelines, in patients with severe alcoholic hepatitis (MDF of 32 or above) who have no contraindications to corticosteroid use, consideration should be given to the oral administration of prednisolone (40 mg/day) to improve 28-day mortality.

• #21 Alcoholic Hepatitis: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2022/0400/p412.html

  Given the high rate of concomitant infections in patients with alcoholic hepatitis, it is reasonable to administer broad-spectrum empiric antibiotics while awaiting culture results. After workup and culture findings rule out alternative diagnoses and any infections have been treated successfully, guidelines support initiating oral corticosteroids (prednisolone, 40 mg per day, or methylprednisolone, 32 mg per day) in patients with severe alcoholic hepatitis. […] There is growing support for early liver transplantation in some patients with severe alcoholic hepatitis, rather than requiring six months of alcohol abstinence and engagement in alcohol cessation counseling.

• #21 Alcoholic Hepatitis: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2022/0400/p412.html

  Treatment for moderate disease primarily consists of supportive care, including alcohol cessation and nutritional support. Corticosteroids are recommended for severe alcoholic hepatitis. Responsiveness to corticosteroid therapy should be evaluated using the Lille score on day 7 of treatment. […] Abstinence from alcohol is the mainstay of treatment. Clinicians should counsel all patients on alcohol cessation, offer medications for alcohol use disorder when appropriate, and consider early consultation with a substance abuse counselor, social worker, and/or psychiatrist, depending on institutional resources. […] Nutritional support can include low-volume intravenous fluids for dehydration; intravenous or oral thiamine to decrease risk of Wernicke encephalopathy; and supplemental folate, vitamin B6, vitamin B12, and zinc for common vitamin deficiencies. Daily energy intake of 35 to 40 kcal per kg of body weight and daily protein intake of 1.2 to 1.5 g per kg of body weight are recommended.

• #22 Treatment of alcoholic liver disease | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-treatment-alcoholic-liver-disease-S1665268119318836

  Drug Therapy […] Glucocorticoids may be useful in the treatment of severe alcoholic hepatitis with DF ***entity***32 or hepatic encephalopathy but should not be used in patients with gastrointestinal bleeding requiring transfusion, active infection and probably in hepatorenal syndrome. […] Pentoxifylline is an excellent alternative to glucocorticoid therapy particularly in patients who are at risk for hepatorenal syndrome (worsening creatinine, infection, hyponatremia). […] Liver transplantation […] Liver transplantation in alcoholic cirrhotics remains a highly controversial and sensitive issue. […] Despite the variation in selection criteria amongst the different centers, it has been conclusively shown that the outcome of liver transplantation in alcoholic cirrhosis is equivalent to those transplanted for other indications. […] A period of alcohol abstinence is considered essential before these patients can be listed for liver transplantation. […] Finally, liver transplant should be considered in these patients when appropriate, since it has been shown to be very effective in carefully selected patients who have discontinued drinking.

• #22 Treatment of alcoholic liver disease | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-treatment-alcoholic-liver-disease-S1665268119318836

  Lifestyle modifications including abstinence […] Establishment and maintenance of abstinence is probably the most important treatment modality in ALD. […] Even reducing alcohol consumption has been shown to improve projected survival in ALD. […] In summary, therapeutic lifestyle changes in ALD include: ideally, abstinence from alcohol or at least significant reduction in alcohol consumption, weight control and quitting smoking. […] Nutritional support […] In summary, nutritional supplementation clearly improves nutritional status and may enhance liver function and decrease morbidity and mortality in some patients. […] Assessment of nutritional status and nutritional supplementation should be aggressively pursued in both inpatients and outpatients with ALD, especially in patients with more severe disease such as severe alcoholic hepatitis or cirrhosis.

• #23 Treatment of Alcoholic Liver Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5572973/

  Several new therapies have been studied in patients with alcoholic hepatitis. One is granulocyte colony-stimulating factor (GCSF). In several studies from India, the use of GCSF along with either prednisolone or pentoxifylline, depending on the study, improved short-term (2-3 months) survival. In my opinion, studies of GCSF should be performed in the United States or in the Western world to confirm its effectiveness in a Western population before the therapy can be broadly recommended. One of the potential advantages of GCSF is its reported safety. […] N-acetylcysteine (NAC) has also been studied for the treatment of alcoholic hepatitis. In a meta-analysis, NAC by itself did not improve survival in alcoholic hepatitis. However, one study showed that treatment with prednisolone and NAC was better than treatment with prednisolone alone at 1 month, although the survival benefit was lost by 6 months. In my opinion, additional clinical trials of NAC are needed before it can be recommended for patients with alcoholic hepatitis.

• #23 Treatment of Alcoholic Liver Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5572973/

  Patients with alcoholic cirrhosis who have been abstinent for 6 months or more are potential candidates for liver transplantation as long as they meet the other criteria for transplantation. The recidivism rate among abstinent alcoholic cirrhotic patients is roughly 10%. Alcohol use after transplantation is often minimal and does not affect organ survival; however, in a small number of patients, there is a significant return to alcohol use. Nevertheless, abstinent patients with decompensated alcoholic cirrhosis are generally considered to be suitable candidates for liver transplantation if they have fulfilled all of the standard components of the transplant evaluation process.

• #24 Current Management of Alcohol-Associated Liver Disease – Gastroenterology & Hepatology

  https://www.gastroenterologyandhepatology.net/archives/november-2020/current-management-of-alcohol-associated-liver-disease/

  Only a few medical therapies exist for AH, and even fewer have shown significant benefit. Management of chronic ALD is similar to that of other chronic liver diseases, with a focus on alcohol abstinence. […] The STOPAH trial, conducted in the United Kingdom in 2015, was a multicenter, prospective, double-blind, randomized, controlled study evaluating pentoxifylline and prednisolone for the treatment of AH. […] Although prednisolone can be considered for short-term mortality benefit, its long-term benefit is unknown. […] The antioxidant N-acetylcysteine has been studied in combination with glucocorticoids in a multicenter, randomized, controlled trial. […] Although there appears to be benefit in regard to hepatorenal syndrome and short-term survival, further studies are needed to recommend this regimen for the long-term treatment for acute AH.

• #24 Current Management of Alcohol-Associated Liver Disease – Gastroenterology & Hepatology

  https://www.gastroenterologyandhepatology.net/archives/november-2020/current-management-of-alcohol-associated-liver-disease/

  Nutritional therapy be provided to patients with severe AH to improve patient overall survival. […] Zinc supplementation in malnourished patients with severe AH is recommended to improve clinical outcomes. […] When medical therapy fails, early LT is a promising treatment option for severe AH, with significantly improved survival rates compared to patients who do not undergo LT. […] Further work is needed to develop more accurate tools in selecting appropriate candidates for LT in ALD.

• #25 Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives

  https://www.mdpi.com/2227-9059/10/10/2530

  Given the chronic pro-inflammatory state in patients with advanced forms of ALD, AASLD and EASL both proposed using corticosteroids for patients with severe AH based on their anti-inflammatory properties, which have shown a significant improvement in shortening 28-day mortality. […] Recent studies have also revealed a reduction in short-term mortality of patients with severe AH, supporting the promising therapeutic efficacy of corticosteroids against alcohol-associated liver disease. […] However, the limitation still exists as a substantial proportion of AH patients do not properly respond to conventional corticosteroid therapy, which may partially account for its poor performance in reducing 6-month mortality. […] Therefore, careful consideration should be taken when administering corticosteroids in patients with high risks of infection, as this can greatly contribute to increased mortality rates.

• #26 Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives

  https://www.mdpi.com/2227-9059/10/10/2530

  Given the importance and significance of oxidative stress in ALD progression, some antioxidant molecules that may enhance glutathione level have been initially considered promising therapeutic targets for the early stages of ALD. […] Metadoxine, a hepatoprotective medicine with pyridoxine-pyrrolidone carboxylate moiety, has also been used to treat acute and chronic alcohol intoxication and has shown an improvement in reducing both short- and long-term mortality in AH patients when used in combination with either steroids or pentoxifylline. […] For subpopulations of patients with ALD who do not properly respond to medical therapies, early liver transplantation (typically before 6 months of alcohol abstinence) can be another potential therapeutic option, as supported by results from some clinical studies demonstrating remarkable improvement in the survival of patients with severe AH or alcoholic cirrhosis.

• #27 Managing medicines in alcohol-associated liver disease: a practical review

  https://australianprescriber.tg.org.au/articles/managing-medicines-in-alcohol-associated-liver-disease-a-practical-review.html

  The decision to prescribe benzodiazepines in alcohol-associated liver disease should be made on a case-by-case basis as patients may be at increased risk of harm due to pharmacodynamic interactions. […] Alcoholic hepatitis can be a life-threatening condition associated with heavy alcohol use. […] Mortality associated with alcoholic hepatitis is high and immediate referral to hospital for assessment, support and treatment is essential. […] In all stages of alcohol-associated liver disease, vitamin B1 (thiamine) supplementation is strongly recommended to prevent neurological complications like Wernicke-Korsakoffs syndrome. […] Supplementation of fat-soluble vitamins (A, D, E and K) is not routinely recommended, except for vitamin D deficient patients with cirrhosis or bone disease. […] The benefits of supplementing other micronutrients including ascorbic acid, magnesium and selenium are debated and they are not routinely recommended in clinical practice. […] Evidence supports zinc supplementation to correct deficiency in alcohol-associated liver disease, especially in people with cirrhosis and alcoholic hepatitis.

• #28 Alcoholic Liver Disease | UCSF Department of Surgery

  https://hpbsurgery.ucsf.edu/condition/alcoholic-liver-disease

  Treatment strategies for ALD include lifestyle changes to reduce alcohol consumption, cigarette smoking, and obesity; nutritional therapy; pharmacological therapy; and possibly liver transplantation (in case of cirrhosis). […] Abstinence from alcohol is vital to prevent further liver injury, scarring, and possibly liver cancer; it appears to benefit patients at each stage of the disease. […] Although only a few studies have looked specifically at the effects of abstinence on the progression of ALD, virtually every one has shown that abstaining from alcohol is beneficial. […] To prevent these deficiencies, clinicians should provide alcoholics with a balanced diet. […] Dietary supplements may prevent or relieve some of alcohol’s harmful effects. […] For example, brain damage resulting from a lack of vitamin B1, which can lead to conditions such as Wernicke-Korsakoff syndrome, can be reversed to some extent.

• #29 Alcoholic Liver Disease | UCSF Department of Surgery

  https://hpbsurgery.ucsf.edu/condition/alcoholic-liver-disease

  Because vitamin B1 generally can be administered safely, clinicians often recommend that all alcoholics undergoing treatment receive 50 milligrams of thiamine per day (either by injection if the patients are hospitalized or by mouth). […] Alcoholics also should receive supplements of vitamins B2 (riboflavin) and B6 (pyridoxine) in dosages found in standard multivitamins. […] Studies using animals are helping researchers find other dietary supplements that may help in the treatment of liver disease. […] An important antioxidant, glutathione, or GSH, cannot be used as a supplement because this substance cannot directly enter the cells threatened by oxidative stress. […] However, researchers are using a precursor compound, the molecule S-adenosylmethionine (SAMe), which can enter the cells and then break down to form the helpful antioxidant.

• #29 Alcoholic Liver Disease | UCSF Department of Surgery

  https://hpbsurgery.ucsf.edu/condition/alcoholic-liver-disease

  When SAMe was given to patients with alcoholic cirrhosis in a clinical trial, they were significantly less likely to die or require a liver transplant within the next 2 years, compared with patients who had received an inactive substance (that is, a placebo). […] No FDA-approved therapy exists for either alcoholic cirrhosis or alcoholic hepatitis. […] However, several drugs have been used „off label,” including pentoxifylline (PTX) and corticosteroids. […] PTX was shown to be effective in patients with severe alcoholic hepatitis. […] Liver transplantation currently is the only definitive treatment for severe (end stage) liver failure. […] ALD patients must undergo a thorough evaluation to determine whether they are suitable candidates for transplant. […] For transplantation to be successful in alcoholic patients it is essential that they remain abstinent after the surgery and comply with a demanding medical regimen (e.g., consistently take the necessary antirejection medications).

• #30 Alcoholic liver disease: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000281.htm

• #31 Alcoholic liver disease Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/alcoholic-liver-disease

  LIFESTYLE CHANGES […] Some things you can do to help take care of your liver disease are: […] Stop drinking alcohol. […] Eat a healthy diet that is low in salt. […] Get vaccinated for diseases such as influenza, hepatitis A and hepatitis B, and pneumococcal pneumonia. […] Talk to your provider about all medicines you take, including herbs and supplements and over-the-counter medicines. […] MEDICINES FROM YOUR DOCTOR […] „Water pills” (diuretics) to get rid of fluid buildup […] Vitamin K or blood products to prevent excess bleeding […] Medicines for mental confusion […] Antibiotics for infections […] OTHER TREATMENTS […] Endoscopic treatments for enlarged veins in the esophagus (esophageal varices) […] Removal of fluid from the abdomen (paracentesis) […] Placement of a transjugular intrahepatic portosystemic shunt (TIPS) to repair blood flow in the liver

• #32 Alcohol-Related Liver Disease – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/alcohol-related-liver-disease/alcohol-related-liver-disease

  General management emphasizes supportive care. A nutritious diet and vitamin supplements (especially B vitamins) are important during the first few days of abstinence. Alcohol withdrawal requires use of benzodiazepines (eg, diazepam). In patients with advanced alcohol-related liver disease, excessive sedation can precipitate portosystemic encephalopathy and thus must be avoided. […] Severe acute alcoholic hepatitis commonly requires hospitalization, often in an intensive care unit, to facilitate enteral feeding (which can help manage nutritional deficiencies) and to manage specific complications (eg, infection, bleeding from esophageal varices, specific nutritional deficiencies, Wernicke encephalopathy, Korsakoff psychosis, electrolyte abnormalities, portal hypertension, ascites, portosystemic encephalopathy).

• #33 As alcoholic liver disease rises, how do we treat it more effectively?

  https://harvardpublichealth.org/equity/how-we-treat-alcohol-related-liver-disease-is-unfair-time-for-change/

  Despite evidence that early liver transplant dramatically improves survival rates, many providers are still reluctant to do it. […] The answer lies in adopting a better approach to managing alcohol use disorderboth to prevent the development of liver disease in the first place, and improve health outcomes for patients who do progress to liver disease and need a transplant. […] First, we must change the eligibility rules for transplant. […] To be eligible for a transplant, patients with alcohol-related liver disease must stop drinking entirely for at least six months, commonly referred to as the 6-month rule. […] The strict rules surrounding liver transplants are in place to select patients who are unlikely to start drinking again post-transplant, as a return to heavy drinking risks severe damage to a transplanted liver.

• #33 As alcoholic liver disease rises, how do we treat it more effectively?

  https://harvardpublichealth.org/equity/how-we-treat-alcohol-related-liver-disease-is-unfair-time-for-change/

  I met Michael during a medical school rotation at a veterans hospital in early 2021. He had alcohol-related hepatitis, a severe, acute inflammation of the liver caused by excessive alcohol use. Nearly half of patients with this condition die within six months of diagnosis. […] Treatment options for alcohol-related hepatitis are few, except for one that almost always works but is rarely used: a liver transplant. […] To prevent deaths, we must invest in better disease prevention and treatment. That includes changing the rules around who gets a liver transplant, and integrating addiction treatment into comprehensive transplant care. […] Recently, alcohol-related liver disease became the leading indication for a liver transplant in the U.S. […] Both types of liver disease are life threatening and both can be cured by a liver transplant.

• #34 Alcohol-related liver disease and liver transplantation

  https://kosinmedj.org/journal/view.php?number=1193

  Establishing abstinence before LT is the most important starting point. […] Behavioral therapy is the mainstay of AUD treatment in LT candidates and recipients. […] The American Psychiatric Association (APA) has suggested the AUD treatment guidelines. […] Naltrexone blocks the effects of opioid receptors and suppresses alcohol intake and desire. […] Acamprosate has shown efficacy in treating AUD, especially for preventing alcohol relapse in previously sober patients. […] Disulfiram has hepatotoxic effect; therefore, it is not recommended for use in patients with advanced liver disease. […] Although ALD is one of the most common causes of LT in the US and Europe, LT has traditionally been not considered as an option for patients with ALD due to organ shortage and concerns for relapse.

• #35 As alcoholic liver disease rises, how do we treat it more effectively?

  https://harvardpublichealth.org/equity/how-we-treat-alcohol-related-liver-disease-is-unfair-time-for-change/

  However, an arbitrary period of abstinence shouldn’t be a prerequisite for transplant eligibility, and a relapse shouldn’t automatically disqualify a patient from getting a liver transplant. […] Mandatory abstinence periods are just one of the many issues that patients with alcohol-related liver disease must contend with when pursuing a liver transplant. […] While it is important to get information from patients that helps select candidates for liver transplant who will have good outcomes, it is also important to set reasonable expectations for patients, and establish open and honest communication regarding an individual’s alcohol use. […] We must acknowledge the growing prevalence of alcohol-related liver disease and better integrate addiction treatment within transplant centers. […] By developing trust with patients like Michael and Sarah, we could detect alcohol relapse early, and intervene to meet the needs of these patients. […] We can and should work to ensure all patients succeed following transplant, regardless of their race, socio-economic status, or type of liver disease.

• #36 Alcohol-related liver disease and liver transplantation

  https://kosinmedj.org/journal/view.php?number=1193

  The survival rates of patients at 1, 3, 5, and 10 years after LT for AC are reported to be 84%89%, 78%83%, 73%79%, and 58%73%, respectively. […] The prevalence of alcohol relapse varies from 10% to 90% in several studies due to differences in the definition of relapse and follow-up time after LT. […] A meta-analysis showed an alcohol relapse and heavy alcohol relapse rate of 22% and 14%, respectively, at a mean follow-up of 24 months after LT. […] The most effective methods for identifying alcohol relapse post-LT are the clinical interviews and the Alcohol Timeline Followback questionnaire; however, more research on the utility of combining several methods needs to be conducted. […] It has been considered that continuous intervention before and after LT is extremely important, and this can be achieved by the accurate identification of risk factors for recurrence after LT. […] A multidisciplinary team approach in combination with biochemical screening, can identify early recurrence and improves post-LT survival in patients with ALD.

• #37 Alcohol Liver Disease Clinic | Baylor Scott & White Health

  https://www.bswhealth.com/specialties/liver-diseases/alcohol-liver-disease-clinic

  Complete care for alcohol-associated liver disease […] Our team is dedicated to meeting the growing need for alcohol-associated liver disease care in our community. As the first program of its kind in North Texas, our Alcohol Liver Disease Clinic offers specialized care and support when you have both liver disease and alcohol use disorder. […] With a team of multiple specialists, we provide alcohol liver disease care near you, including: […] Management of alcohol-associated cirrhosis […] Treatment for alcohol use disorder […] Transplant care for highly selected cases […] By bringing your care team together in one center, we offer a holistic approach to alcohol-associated liver disease treatment in North Texas. We not only care for your physical needs but also the mental, emotional and social factors that affect your health and well-being.

• #38

  https://journals.lww.com/hep/fulltext/2020/01000/diagnosis_and_treatment_of_alcohol_associated.25.aspx

  Because abstinence is the single most important factor in improving survival from ALD, multidisciplinary management with addiction specialists and referral to treatment for AUD, particularly in patients with moderate to severe AUDs or clinically evident ALD, is mandatory. […] There are a wide variety of alcohol use disorder treatments available to patients, although relatively few have been studied in patients with ALD. Major categories of treatment include inpatient alcohol rehabilitation, group therapies, individual therapy, family/couples counseling, and mutual aid societies (such as Alcoholics Anonymous). […] Psychosocial treatment has been studied in a limited fashion in ALD. A recent systematic review of treatment trials in ALD found that integrating AUD treatment providers alongside medical providers in clinic produced better abstinence rates than usual care, which typically means a referral to a treatment provider outside the liver center.

• #39

  https://journals.lww.com/hep/fulltext/2020/01000/diagnosis_and_treatment_of_alcohol_associated.25.aspx

  Referral to AUD treatment professionals is recommended for patients with advanced ALD and/or AUD, to ensure access to the full range of AUD treatment options. […] Multidisciplinary, integrated management of ALD and AUD is recommended and improves rates of alcohol abstinence among patients with ALD. […] Based on limited data, the use of acamprosate or baclofen can be considered for the treatment of AUD in patients with ALD.

• #40 UCF Physicians Find Alternative Treatment Option for Alcohol-Related Liver Disease | University of Central Florida News

  https://www.ucf.edu/news/ucf-physicians-find-alternative-treatment-option-for-alcohol-related-liver-disease/

  A commonly prescribed pain reliever could help patients with liver damage from alcohol use disorder, UCF research shows. […] Two UCF-trained physicians who are dedicating their careers to addiction medicine and digestive health are receiving national attention for their discovery that an off-label medicine could help patients with alcohol-related liver disease. […] Raj Shah and Richard Henriquez found that gabapentinoids, a family of drugs used to prevent seizures and commonly used for nerve pain, reduced alcohol withdrawal symptoms and slowed the progressions of liver disease better than another FDA-approved drug for alcohol use disorder. […] The physician researchers hope that their findings will encourage more doctors to consider using gabapentinoids to treat patients with alcohol use dependency before they suffer significant liver damage.

• #41 UCF Physicians Find Alternative Treatment Option for Alcohol-Related Liver Disease | University of Central Florida News

  https://www.ucf.edu/news/ucf-physicians-find-alternative-treatment-option-for-alcohol-related-liver-disease/

  Gabapentin treats pain by soothing the nervous system. As such, it may address mental health issues such as anxiety that can lead patients to drink heavily and subsequently damage their livers, Shah told media at the national conference. […] If we’re able to, with gabapentin, kill two birds with one stone able to treat their pains as well as their alcohol use disorder then it’s warranted, using gabapentin versus just using acamprosate, he says. […] Both researchers said more studies are needed to replicate their findings. They emphasize that physicians should not conclude that gabapentinoids are better than other FDA-approved drugs to treat alcohol use disorder, only that it is another option for patients and providers.

• #42 Hope for treating alcohol-related liver disease

  https://sciencenews.dk/en/hope-for-treating-alcohol-related-liver-disease

  Millions of people worldwide have alcohol-related liver disease from long-term excessive alcohol consumption, and many die from this. Until now, there was no optimal treatment. However, this may change after a trial with rifaximin-a, an antibiotic that has shown promising results. A researcher involved in the study says that the antibiotic may also be used for other liver diseases. […] Our results are amazing because treatment with rifaximin- convincingly reduced scarring of the liver among people with alcohol-related liver disease. If we can confirm our findings in a larger study, we could potentially treat millions of people who have no treatment options today, explains Mads Israelsen, Postdoctoral Fellow at the Centre for Liver Research, Odense University Hospital. […] Treatment with rifaximin- slowed the progression of alcohol-related liver disease.

• #43 Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement | Nature Reviews Gastroenterology & Hepatology

  https://www.nature.com/articles/s41575-024-00936-x

  Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined as 4 or more drinks per day (56g) or 8 (112g) or more drinks per week for women and 5 or more drinks per day (70g) or 15 (210g) or more drinks per week for men. […] Although abstinence from alcohol after diagnosis of ALD improves life expectancy and reduces the risk of decompensation of liver disease, few studies have evaluated whether treatment of alcohol use disorders will reduce progression of liver disease and improve liver-related outcomes. […] The task force conducted extensive reviews of relevant literature on alcohol use disorders and ALD. […] Evidence from observational studies suggests that reducing alcohol use should improve both liver-related and alcohol-related outcomes in patients with ALD, but this hypothesis requires empirical confirmation and clinical trials are urgently needed.

• #44 Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement | Nature Reviews Gastroenterology & Hepatology

  https://www.nature.com/articles/s41575-024-00936-x

  The type and duration of treatment must be clear. Treatments that are aimed solely at improving liver function or treating complications of liver disease should be evaluated separately from treatments aimed at reducing alcohol consumption or managing AUD. […] Any pharmacotherapy study for patients with AUD and ALD should also consider potential drug-alcohol interactions that may limit efficacy or introduce safety concerns. […] Many behavioural treatments for AUD can be delivered in residential (for example, inpatient), intensive outpatient and outpatient settings, but relatively few randomized clinical trials have been conducted with patients with comorbid AUD and ALD. […] All trials for ALD should acknowledge explicitly the benefits of reduced drinking and the potential need for AUD treatment. […] For clinical trials studying ALD, testing distinct AUD treatment (treatments) including pharmacological, behavioural or cognitive should be pre-specified in the protocol with stratified results if more than one treatment modality for AUD is pre-specified.

• #45 How to Cleanse Your Liver from Alcohol Use | What You Should Know

  https://www.therecoveryvillage.com/alcohol-abuse/repair-liver-alcohol-use/

  While cirrhosis scars from excessive drinking are irreversible, quitting alcohol and leading a healthier lifestyle can help your liver heal from fatty liver disease and alcoholic hepatitis. […] The sooner a person stops drinking, the better off their body will be in the long run. Once the liver undergoes fibrotic changes, it cannot be fully repaired. […] Alcoholic fatty liver treatment mainly relies on changes to your lifestyle. These changes can include: quitting alcohol completely, eating a healthy diet, weight loss, if you are overweight, and exercise, which may reduce the amount of fat in the liver. […] Alcoholic hepatitis treatment involves stopping the use of alcohol and supporting the liver as it heals. Alcohol cessation is a crucial part of the initial treatment because as long as alcohol is used, there will be more inflammation. The good news is that, over time, the inflammation of the liver can subside once alcohol use is stopped.

• #46 Alcohol-Associated Liver Disease: Causes & Symptoms

  https://liverfoundation.org/liver-diseases/alcohol-associated-liver-disease/

  The first step in treating alcohol-associated liver disease is to stop drinking all alcohol. If fatty liver or alcoholic hepatitis are present, the only way there is a chance that the damage will reverse is to discontinue drinking. […] It may be advisable to speak with your doctor about medical oversight when ceasing drinking. Medications may help if someone is alcohol dependent and will go through withdrawal. If alcohol dependence is an issue, treatment to stop drinking could include counseling, entering a treatment center, and seeking support programs such as AA. […] Treatment for the liver disease itself will depend upon the diagnosis. Alcohol-associated fatty liver will usually reverse on its own without treatment if the person stops drinking alcohol. […] Alcohol-associated hepatitis may be treated with medication, but the medical provider would have to assess whether such treatments would be appropriate because they can have serious side effects.

• #47 Alcohol-Associated Liver Disease: Causes & Symptoms

  https://liverfoundation.org/liver-diseases/alcohol-associated-liver-disease/

  If the damage has progressed to cirrhosis, the liver is no longer performing its jobs normally. One main function of the liver is filtering toxins from the body. Treatment for cirrhosis often involves treating complications. […] Nutrition therapy may be offered to people with alcohol-associated liver disease. The doctor may refer their patients to a dietitian who can help them plan nutritious meals. If a person is unable to eat, nutrients can be provided with the use of a feeding tube. […] People with cirrhosis may be candidates for transplant. Each patient is assessed individually based upon their overall health status, and if a doctor feels that transplant may be an option, he or she will refer that patient to a transplant center for a thorough medical, psychological, and financial evaluation. To receive a transplanted liver, the liver transplant team typically must be certain that the patient will take care of the new liver and never return to drinking alcohol.

• #48 Alcohol-Related Liver Disease Program | Temple Health

  https://www.templehealth.org/services/alcohol-related-liver-disease

  In its early stages, liver damage caused by alcohol-related liver disease may actually be reversed. […] The Temple Alcohol-Related Liver Disease Program helps you overcome the effects of alcoholic liver disease. […] Successful treatment requires strong social support. […] Our Alcohol-Related Liver Disease Program includes: Comprehensive evaluation of all patients, regardless of drinking history, Achievable treatment plans tailored to your lifestyle, Support programs, including a dietitian or nutritionist and access to a psychologist in-person or online, Reassurance that you have an entire team of medical specialists on your side, should you need it. […] If not treated, alcoholic liver disease can advance to different stages, including fatty liver, alcoholic hepatitis and cirrhosis, or end-stage liver disease.

• #49 Alcohol-Related Liver Disease Program | Temple Health

  https://www.templehealth.org/services/alcohol-related-liver-disease

  If your condition advances to end-stage liver disease, you may require a liver transplant. […] The best candidates for alcoholic liver disease treatment are those who show motivation and commitment to make healthy, sustainable lifestyle changes. […] Well support you with the most advanced treatments available, including: Cognitive behavior therapy, Medication, including disulfiram, naltrexone, acamprosate, Nutritional support, Steroids, Liver transplant.

Zobacz więcej